ЛЕКАРСТВЕННОЕ ЛЕЧЕНИЕ БОЛЬНЫХ РАКОМ ЯИЧНИКОВ ЧАСТЬ 3. АНТИАНГИОГЕННЫЕ ПРЕПАРАТЫ, ИНГИБИТОРЫ ФОЛАТНЫХ РЕЦЕПТОРОВ, PARP, WEE1 И ИММУНОТЕРАПИЯ ПЛАТИНОРЕЗИСТЕНТНЫХ РЕЦИДИВОВ; ГОРМОНОТЕРАПИЯ РАКА ЯИЧНИКОВ

DOI: https://doi.org/10.29296/25877313-2018-09-02
Номер журнала: 
9
Год издания: 
2018

С.В. Хохлова д.м.н., ст. науч. сотрудник, отделение химиотерапии, ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России (Москва) E-mail: svkhokhlova@mail.ru Д.Н. Кушлинский к.м.н., онкогинеколог, отделение инновационной онкологии и гинекологии, ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. В.И. Кулакова» Минздрава России (Москва)

Представлены современные данные зарубежной и отечественной литературы, касающиеся вопросов лекарственного лечения больных раком яичников. Рассмотрены клиническая значимость антиангиогенных препаратов, ингибиторов фолатных рецепторов, PARP, WEE1 и иммунотерапия платинорезистентных рецидивов. Раздел обзора посвящен гормонотерапии рака яичников. С учетом ключевых клинических, морфологических и молекулярно-биологических характеристик рака яичников обсуждаются представленные в литературе данные по прогнозу лекарственной терапии этих новообразований

Ключевые слова: 
рак яичников
лекарственная терапия
антиангиогенные препараты
ингибиторы фолатных рецепторов
PARP
WEE1
иммунотерапия
платинорезистентные рецидивы
гормонотерапия

Список литературы: 
  1. Edwards S.J., Barton S., Thurgar E., Trevor N. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation. Health Technol. Assess. 2015;19(7):1-480.
  2. Buda A., Floriani I., Rossi R., Colombo N., Torri V., Conte P.F., Fossati R., Ravaioli A., Mangioni C. Randomised controlled trial comparing single agent paclitaxel vs.epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum based chemotherapy: an Italian Collaborative Study from the Mario Negri Institute, Milan, G.O.NO. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group. Br. J. Cancer. 2004;90(11):2112-2127.
  3. Lortholary A., Largillier R., Weber B., Gladieff L., Alexandre J., Durando X., Slama B., Dauba J., Paraiso D., Pujade-Lauraine E. GINECO group France. Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO). Ann. Oncol. 2012; 23(2):346-352.
  4. Pujade-Lauraine E., Hilpert F., Weber B., Reuss A., Poveda A., Kristensen G., Sorio R., Vergote I.B., Witteveen P., Bamias A., Pereira D., Wimberger P., Oaknin A., Mirza M.R., Follana P., Bollag D.T., Ray-Coquard I. AURELIA: a randomized phase III trial evaluating bevacizumab plus chemotherapy for platinum resistant ovarian cancer / E. Pujade Lauraine, F. Hilpert, et. al. J. Clin. Oncol. 2012; 30:LBA 5002.
  5. Witteveen P., Lortholary A., Fehm T., Poveda A., Reuss A., Havsteen H., Raspagliesi F., Vergote I., Bamias A., Pujade-Lauraine E. Final overall survival (OS) results from AURELIA, an open label randomised phase III trial of chemotherapy (CT) with or without bevacizumab (BEV) for platinum resistant recurrent ovarian cancer (OC). Eur. J. Cancer. 2013; 49:S3-S4.
  6. Monk B.J., Poveda A., Vergote, Raspagliesi F., Fujiwara K., Bae D.S., Oaknin A., Navale L., Warner D.J., Oza A.M. A phase III, randomized, double blind trial ofweekly paclitaxel plus the angiopoietin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer: TRINOVA 1. Eur. J. Cancer. 2013; 49(1):S18.
  7. Karlan B.Y., Oza A.M., Richardson G.E., Provencher D.M., Hansen V.L., Buck M., Chambers S.K., Ghatage P., Pippitt C.H.Jr., Brown J.V., Covens A., Nagarkar R.V., Davy M., Leath C.A., Nguyen H., Stepan D.E., Weinreich D.M., Tassoudji M., Sun Y.N., Vergote I.B. Randomized, double blind, placebo controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J. Clin. Oncol. 2012; 30(4):362-371.
  8. Gotlieb W.H., Amant F., Advani S., Goswami C., Hirte H., Provencher D., Somani N., Yamada S.D., Tamby J.F., Vergote I. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double blind, placebo controlled study. Lancet Oncol. 2012; 13(2):154-162.
  9. Colombo N., Mangili G., Mammoliti S., Kalling M., Tholander B., Sternas L., Buzenet G., Chamberlain D. A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites. Gynecol. Oncol. 2012; 125(1):42-47.
  10. Friedlander M., Hancock K.C., Rischin D., Messing M.J., Stringer C.A., Matthys G.M., Ma B., Hodge J.P., Lager J.J. A phase II, open label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol. Oncol. 2010; 119(1):32-37.
  11. Ledermann J.A., Hackshaw A., Kaye S., Jayson G., Gabra H., McNeish I., Earl H., Perren T., Gore M., Persic M., Adams M., James L., Temple G., Merger M., Rustin G. Randomized phase II placebo controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J. Clin. Oncol. 2011; 29(28):3798-3804.
  12. Gordon A.N., Finkler N., Edwards R.P., Garcia A.A., Crozier M., Irwin D.H., Barrett E. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int. J. Gynecol. Cancer. 2005; 15(5):785-792.
  13. Schilder R.J., Pathak H.B., Lokshin A.E., Holloway R.W., Alvarez R.D., Aghajanian C., Min H., Devarajan K., Ross E., Drescher C.W., Godwin A.K. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol. Oncol. 2009; 113(1):21-27.
  14. Seiden M.V., Burris H.A., Matulonis U., Hall J.B., Armstrong D.K., Speyer J., Weber J.D., Muggia F. A phase II trial of EMD72000 (matuzumab), a humanized anti EGFR monoclonal antibody, in patients with platinum resistant ovarian and primary peritoneal malignancies. Gynecol. Oncol. 2007; 104(3):727-731.
  15. Posadas E.M., Lie M.S..l, Kwitkowski V. et al.A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer. 2007.; 109(7):1323-1330.
  16. Schilder R.J., Pathak H.B., Lokshin A.E. et al. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol. 2009; 113(1):21-27.
  17. Wagner U., du Bois A., Pfisterer J. et al. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy — a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecol Oncol. 2007; 105(1):132-137.
  18. Vergote I.B., Jimeno A., Joly F., Katsaros D., Coens C., Despierre E., Marth C., Hall M., Steer C.B., Colombo N., Lesoin A., Casado A., Reinthaller A., Green J., Buck M., Ray-Coquard I., Ferrero A., Favier L., Reed N.S., Cure H., Pujade-Lauraine E. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first line platin based chemotherapy for ovarian carcinoma: A GCIG and EORTC GCG study. J. Clin. Oncol. 2014;32(4):320-326.
  19. Bookman M.A., Darcy K.M., Clarke-Pearson D., Boothby R.A., Horowitz I.R. Evaluation of monoclonal humanized anti HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J. Clin. Oncol. 2003; 21(2):283-290.
  20. Gordon M.S., Matei D., Aghajanian C., Matulonis U.A., Brewer M., Fleming G.F., Hainsworth J.D., Garcia A.A., Pegram M.D., Schilder R.J., Cohn D.E., Roman L., Derynck M.K., Ng K., Lyons B., Allison D.E., Eberhard D.A., Pham T.Q., Dere R.C., Karlan B.Y. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J. Clin. Oncol. 2006; 24(26):4324-4332.
  21. Makhija S., Amler L.C., Glenn D., Ueland F.R., Gold M.A., Dizon D.S., Paton V., Lin C.Y., Januario T., Ng K., Strauss A., Kelsey S., Sliwkowski M.X., Matulonis U. Clinical activity of gemcitabine plus pertuzumab in platinum resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J. Clin. Oncol. 2010; 28(7):1215-1223.
  22. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-615.
  23. Ledermann J.A., Canevari S., Thigpen T. Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments. Ann. Oncol. 2015; 26(10):2034-2043.
  24. Gonen N., Assaraf Y.G. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist. Updat. 2012; 15(4):183-210.
  25. Yap T.A., Carden C.P., Kaye S.B. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat. Rev. Cancer. 2009; 9(3):167-181.
  26. Kalli K.R., Oberg A.L., Keeney G.L., Christianson T.J., Low P.S., Knutson K.L. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol. Oncol. 2008; 108(3):619-626.
  27. Ebel W., Routhier E.L., Foley B., Jacob S., McDonough J.M., Patel R.K., Turchin H.A., Chao Q., Kline J.B., Old L.J., Phillips M.D., Nicolaides N.C., Sass P.M., Grasso L. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun. 2007; 7:6.
  28. Armstrong D.K., White A.J., Weil S.C., Phillips M., Coleman R.L. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol. Oncol. 2013; 129(3):452-458.
  29. Vergote I., Armstrong D., Scambia G., Teneriello M., Sehouli J., Schweizer C., Weil S.C., Bamias A., Fujiwara K., Ochiai K., Poole C., Gorbunova V., Wang W., O’Shannessy D., Herzog T.J. A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum- Sensitive Relapse. J. Clin. Oncol. 2016; 34(19):2271-2278.
  30. Naumann R.W., Coleman R.L., Burger R.A., Sausville E.A., Kutarska E., Ghamande S.A., Gabrail N.Y., Depasquale S.E., Nowara E., Gilbert L., Gersh R.H., Teneriello M.G., Harb W.A., Konstantinopoulos P.A., Penson R.T., Symanowski J.T., Lovejoy C.D., Leamon C.P., Morgenstern D.E., Messmann R.A. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 2013; 31(35):4400-4406.
  31. Kaufman B., Shapira-Frommer R., Schmutzler R.K., Audeh M.W., Friedlander M., Balmana J., Mitchell G., Fried G., Stemmer S.M., Hubert A., Rosengarten O., Steiner M., Loman N., Bowen K., Fielding A., Domchek S.M. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J. Clin. Oncol. 2015; 33(3):244-250.
  32. Kaye S.B., Lubinski J., Matulonis U., Ang J.E., Gourley C., Karlan B.Y., Amnon A., Bell-McGuinn K.M., Chen L.M., Friedlander M., Safra T., Vergote I., Wickens M., Lowe E.S., Carmichael J., Kaufman B. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J. Clin. Oncol. 2012; 30(4):372-379.
  33. Do K., Doroshow J.H., Kummar S. Wee1 kinase as a target for cancer therapy. Cell Cycle. 2013; 12(19):3159-3164.
  34. Hirai H., Iwasawa Y., Okada M., Arai T., Nishibata T., Kobayashi M., Kimura T., Kaneko N., Ohtani J., Yamanaka K., Itadani H., Takahashi-Suzuki I., Fukasawa K., Oki H., Nambu T., Jiang J., Sakai T., Arakawa H., Sakamoto T., Sagara T., Yoshizumi T., Mizuarai S., Kotani H. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol. Cancer Ther. 2009; 8(11):2992-3000.
  35. Leijen S., van Geel R.M., Sonke G.S., de Jong D., Rosenberg E.H., Marchetti S., Pluim D., van Werkhoven E., Rose S., Lee M.A., Freshwater T., Beijnen J.H., Schellens J.H. Phase II study with Wee1 inhibitor AZD1775 plus carboplatin in patients with p53 mutated ovarian cancer refractory or resistant (< 3 months) to standard first line therapy. in ASCO Annual Meeting Proceedings. J. Clin. Oncol. 2016; 34(36):4354-4361.
  36. Hamanishi J., Mandai M., Ikeda T., Minami M., Kawagu-chi A., Murayama T., Kanai M., Mori Y., Matsumoto S., Chikuma S., Matsumura N., Abiko K., Baba T., Yamaguchi K., Ueda A., Hosoe Y., Morita S., Yokode M., Shimizu A., Honjo T., Konishi I. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. J. Clin. Oncol. 2015; 33(34):4015-4022.
  37. Varga A., Piha-Paul S.A., Ott P.A., Mehnert J.M., Berton-Rigaud D., Morosky A., Zhao G.Q., Rangwala R.A., Matei D. Pembrolizumab in patients (pts) with PD-L1–positive (PD-L1+) advanced ovarian cancer: Updated analysis of KEYNOTE-028. J. Clin. Oncol. 2017; 35(15):5513.
  38. Lee J.M., Dos Santos Zimmer A., Lipkowitz S., Annunziata C.M., Ho T., Chiou V.L. et al. Phase I study of the PD-L1 inhibitor, durvalumab (MEDI4736; D) in combination with a PARP inhibitor, olaparib (O) or a VEGFR inhibitor, cediranib (C) in women’s cancers (NCT02484404). J Clin Oncol. 2016;34 ((suppl; abstr 3015)
  39. NCT01611558: Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer - Study Results. https://clinicaltrials.gov/ct2/show/re-sults/NCT01611558. Accessed 24 May 2016.
  40. Disis M.L., Patel M.R., Pant S., Infante J.R., Lockhart A.C., Kelly K., Beck J.T., Gordon M.S., Weiss G.J., Ejadi S., Taylor M.H., von Heydebreck A., Chin K.M., Cuillerot J.M., Gulley J.L. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open- label expansion trial. J. Clin. Oncol. 2015; 33(15):5509.
  41. Zheng H., Kavanagh J.J., Hu W., Liao Q., Fu S. Hormonal therapy in ovarian cancer. Int. J. Gynecol. Cancer. 2007; 17(2):325-338.
  42. Abu-Jawdeh G.M., Jacobs T.W., Niloff J., Cannistra S.A. Estrogen receptor expression is a common feature of ovarian borderline tumors. Gynecol Oncol. 1996; 60(2):301-307.
  43. Gershenson D.M., Sun C.C., Iyer R.B., Malpica A.L., Kavanagh J.J., Bodurka D.C., Schmeler K., Deavers M. Hormonal therapy for recurrent low grade serous carcinoma of the ovary or peritoneum. Gynecol. Oncol. 2012; 125(3):661-666.
  44. Rendina G.M., Donadio C., Giovannini M. Steroid receptors and prognostic therapy in ovarian endometrioid carcinoma. Eur. J. Gynaecol. Oncol. 1982; 3(3):241-246.
  45. Perez-Gracia J.L., Carrasco E.M. Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research. Gynecol. Oncol. 2002; 84(2):201-209.